Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.54 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648467 | 0.78 | KDM4E (0.54) | PIK3CGKDM4EALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3340576 | 0.78 | SMN1; SMN2 (0.54) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL12778283 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL19086907 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL8814197 | 0.78 | MCHR1 (0.57) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL22499097 | 0.77 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL30828885 | 0.75 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL3485564 | 0.75 | PIK3CG (0.60) | PIK3CGALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21937449 | 0.74 | MCHR1 (0.60) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL720360 | 0.74 | SMN1; SMN2 (0.50) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | PIK3CG 4041/4885KDM4E 4394/4885ALDH1A1 3008/4885 |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | PIK3CG 3281/4885KDM4E 898/4885ALDH1A1 794/4885 |
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | PIK3CG 3030/4885KDM4E 175/4885ALDH1A1 300/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | PIK3CG 3030/4885KDM4E 175/4885ALDH1A1 300/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | PIK3CG 3076/4885KDM4E 178/4885ALDH1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.